Basic Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Jul 15, 2022; 14(7): 1252-1264
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1252
Figure 2
Figure 2 Expression of claudin 18. 2 in primary pancreatic ductal adenocarcinoma. A: Examples of claudin 18.2 (CLDN18.2)-positive pancreatic ductal adenocarcinoma tissues with 0/none, 1+/weak, 2+/intermediate, and 3+/ strong staining intensity. Scale bar 100 μm; B: Overall expression intensity of claudin 18.2. Eighty-eight (94.6%) primary pancreatic ductal adenocarcinoma tissues showed positivity for CLDN18.2 expression. In the positive cases, most showed compositive immunohistochemistry (IHC)-intensity. Fifty (56.8%) cases were scored up to IHC 3+, 86 (97.7%) cases were scored up to but no higher than IHC 2+, and 77 (87.5%) cases were no higher than IHC 1+; C: Histoscore (H-Score) distribution in the study. Minimum H-Score was 0; Maximum H-score was 292. Median H-score of positive tumors was 150.